API | refametinib

refametinib Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Chemistry

SMILES: COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C3(C[C@H](O)CO)CC3
InChIKey: RDSACQWTXKSHJT-NSHDSACASA-N
Mol. Mass: 572.34
ALogP: 3.48 Partition coefficient
ChEMBL Molecules:

refametinib

None

More Chemistry

Pharmacology

Mechanisms of Action:
- Dual specificity mitogen-activated protein kinase kinase 1 (Homo sapiens) ^UniProt
- Dual specificity mitogen-activated protein kinase kinase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bay869766 | bay 869766 | bay-869766 | bay-86-9766 | bay86-9766 | n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide | rdea119 | rdea 119 | rdea-119 | refametinib

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Biliary Tract Neoplasms (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Drug Interactions (Phase 1)

Neoplasms (Phase 1/Phase 2)

Pancreatic Neoplasms (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 13
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue